Plethysmograph - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The plethysmograph market is projected to expand from USD 89.46 million in 2025 and USD 94.15 million in 2026 to USD 128.04 million by 2031, registering a CAGR of 6.34% between 2026 and 2031. This report is segmented by Product Type (Body Plethysmographs, Photo Plethysmographs, Impedance Plethysmographs, and More), Application (Pulmonary Function Testing, Cardiovascular Disease Diagnosis, and More), End-User (Hospitals, Diagnostic Laboratories, and More), and Geography (North America, Europe, Asia-Pacific, Rest of the World). The Market Forecasts are Provided in Terms of Value (USD).

Global Plethysmograph Market Trends and Insights

Rising Burden of COPD, Asthma, and Other Complex Respiratory Disorders

The plethysmograph market has a strong demand floor because COPD and asthma already affect an estimated 650 million children and adults worldwide, which keeps diagnostic needs broad across both mature and developing care systems. The same medical literature indicates that the prevalence of these respiratory conditions is expected to more than double by 2050, which means care systems are preparing for a larger future pool of patients who require deeper lung assessment than routine spirometry provides. The economic burden adds urgency, with the CHEST Journal estimating that direct global COPD costs were USD 3.9 trillion in 2025 and will rise to USD 24.4 trillion by 2050, making accurate diagnosis a practical cost-control tool rather than an optional add-on. The plethysmograph market benefits because body-based lung-volume testing detects trapped gas behind obstructions and structural damage that gas dilution techniques can miss in patients who often drive the highest treatment burden. As a result, the plethysmograph market is expanding on the back of a disease pattern that is clinically complex, financially costly, and unlikely to ease over the forecast period.

Growing Demand for Gold-Standard Lung Volume Measurement in Pulmonary Labs

The plethysmograph market is also being supported by the continued preference for body plethysmography when clinicians need a noninvasive reference method for lung-volume measurement in difficult respiratory cases. A 2025 peer-reviewed analysis highlighted its higher sensitivity for restrictive ventilatory defects associated with long COVID, which broadens its relevance beyond long-established COPD and asthma testing pathways. The same quality advantage is carried into drug development, because clinical programs increasingly need outcome measures that capture total lung capacity and airway resistance with greater precision than simpler spirometric markers. The plethysmograph market, therefore, gains an additional buyer group in contract research organizations, academic hospitals, and phase II and phase III trial sites that need calibrated systems for protocol consistency.

High Capital Cost and Facility Footprint of Body Plethysmograph Systems

The plethysmograph market still faces a meaningful adoption barrier because traditional body systems remain expensive capital purchases for small hospitals, private practices, and lower-resource diagnostic networks. PulmOne’s 2025 ownership-cost analysis shows that the burden extends beyond acquisition and includes HVAC needs, calibration service contracts, and per-test workflow demands that can limit daily volume. These economics become harder to justify when utilization is uneven, since providers must recover depreciation and service costs through testing volumes that are often lower outside major academic centers. The plethysmograph market, therefore, sees slower penetration in sites that cannot rely on high-volume pulmonary workups or broad payer support, even when clinicians recognize the diagnostic value of full lung-volume testing. Compact designs can ease part of this problem, but the plethysmograph market remains exposed to a capital equation that still favors larger institutions.

Other drivers and restraints analyzed in the detailed report include:

• Wider Adoption of Portable and Point-of-Care Respiratory Diagnostics
• Expanding Use in Occupational and Pre-Employment Respiratory Screening
• Limited Skilled Technicians for Correct Test Execution and Interpretation

Segment Analysis

Body plethysmographs captured 34.41% of the plethysmograph market size in 2025, which reflects their established role in measuring total lung capacity, residual volume, and airway resistance in formal respiratory testing environments. A 2025 peer-reviewed review also reinforced the clinical position of plethysmography-derived total lung capacity in COPD evaluation by showing a strong correlation with residual volume and hyperinflation severity. This keeps the plethysmograph market anchored in high-acuity lung assessment, where the accuracy of lung-volume measurement matters more than the convenience of lower-cost substitutes. It also supports durable demand from hospital laboratories that need reference-grade results for diagnosis, staging, and follow-up.

Air plethysmographs are forecasted to be the fastest-growing product type at 7.73% CAGR from 2026 to 2031, which shows how the plethysmograph market is broadening beyond its traditional respiratory core. Photo plethysmographs and impedance plethysmographs also retain meaningful roles, with photoplethysmography expanding through monitoring applications and impedance-based systems showing clinical utility in lower-extremity artery disease assessment. Venous occlusion and research-oriented systems remain smaller, but they still serve trial work and specialized physiology testing where precise blood-flow response data are needed.

Complete Report Scope:

• By Product Type
  • Body Plethysmographs
  • Photo Plethysmographs
  • Impedance Plethysmographs
  • Air Plethysmographs
  • Venous Occlusion Plethysmographs
  • Other Product Types
• By Application
  • Pulmonary Function Testing
  • Cardiovascular Disease Diagnosis
  • Peripheral Vascular Disease Monitoring
  • Sleep Disorder Assessment
  • Blood Flow Measurement
  • Other Applications
• By End-User
  • Hospitals
  • Diagnostic Laboratories
  • Pulmonary Care Centers
  • Ambulatory Surgical Centers
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World

Geography Analysis

North America accounted for 45.31% of the plethysmograph market share in 2025, which made it the largest regional contributor to revenue. The region benefits from dense pulmonology laboratory networks, broader use of established pulmonary billing codes, and a care environment that supports more formal respiratory workups than many other markets. The United States remains the main country anchor because large hospitals and academic centers can support both the capital cost and the staffing requirements associated with advanced lung-function testing. The plethysmograph market also holds up well in North America because occupational assessment, specialty pulmonary care, and research activity all reinforce the installed base rather than depending on one demand channel alone.

Europe remained the second-largest regional market in 2025 and continued to show steady demand from established respiratory testing systems. The plethysmograph market in Europe benefits from structured clinical practice, strong specialist referral pathways, and a long-standing role for lung-volume measurement in COPD and restrictive disease workups. A 2025 peer-reviewed analysis also linked body plethysmography to higher sensitivity in restrictive ventilatory defects associated with long COVID, which supports continued clinical use across hospital respiratory services. At the same time, the full enforcement environment around the EU Medical Device Regulation in 2024 has raised compliance demands related to clinical evidence, quality systems, and post-market oversight. That regulatory pressure favors better-resourced suppliers in the plethysmograph market and makes it harder for smaller vendors to sustain participation without heavier investment in compliance.

Asia-Pacific is projected to record the fastest plethysmograph market growth at 9.11% CAGR through 2031. The plethysmograph market in the region is being lifted by healthcare infrastructure expansion, a large burden of chronic respiratory disease, and a rising need for specialist diagnostics outside the most established urban hospitals. Outside Asia-Pacific, demand in the Middle East and Africa remains concentrated in the GCC and select academic centers, while South America is led by private hospital demand and occupational health use, where capital budgets allow. The plethysmograph market, therefore, shows a clear regional split, with mature demand concentrated in North America and Europe, and faster incremental expansion coming from Asia-Pacific and selected emerging healthcare systems.

List of Companies Covered in this Report:

• ACI Medical LLC
• BioTekna Srl
• COSMED Srl
• D.E. Hokanson, Inc.
• ELCAT GmbH
• GANSHORN Medizin Electronic GmbH
• Geratherm Medical
• Life Measurement, Inc.
• Medisoft, Inc.
• Medline Industries
• MGC Diagnostics
• Mindray
• Morgan Scientific
• ndd Medizintechnik AG
• Nihon Kohden
• Perimed
• PulmOne Advanced Medical Devices Ltd.
• Schiller
• SCIREQ Scientific Respiratory Equipment Inc.
• Siemens Healthineers
• Vyaire Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support